Progress on Anti-Amyloid Therapies: Roundtable Excerpt 1
Update: 2024-03-06
Description
Decades of research have helped elucidate the roles of amyloid plaques and tau tangles in Alzheimer’s disease, identify biomarkers of underlying pathology, and guide the development of new therapies. In this first of two excerpts from a recent roundtable, Dr. Steven E. Arnold, Massachusetts General Hospital, and Dr. David A. Wolk, Penn Memory Center, review our current understanding of amyloid and tau pathologies and the clinical trial data that led to the recent approval of Leqembi (lecanemab), the first fully FDA-approved drug for Alzheimer’s disease in over 20 years.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
